WANBURYNSEWanbury Limited· PharmaceuticalsLowNeutral
Announced Wed, 10 Jun · 12:36 IST

Wanbury Limited has informed the Exchange regarding a press release dated Jun 10, 2026, titled "Press Release on Quality inspection by the Therapeutic Goods Administration (TGA) at Tanuku, Andhra Pradesh".

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.5%1-day move
₹266.00
prior close
₹263.25
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+0.7+0.9+0.8-3.5+3.7+0.4+2.2+0.2-0.8+7.4+12.8
Up moveDown movePending
AI summary

Wanbury Limited has shared with the exchange a press release dated June 10, 2026, regarding a quality inspection conducted by Australia's Therapeutic Goods Administration (TGA) at its manufacturing facility in Tanuku, Andhra Pradesh. The TGA is Australia's drug and medical product regulator, and inspections like these typically assess whether the facility meets the standards required to supply pharmaceutical products to the Australian market. The actual outcome or findings of the inspection are not detailed in the headline itself. Shareholders would need to refer to the full press release for specific details such as any observations, approvals, or compliance status.

Likely market impact

The market reaction depends entirely on the inspection outcome — a clean approval would be a positive signal for the company's export business to Australia, while any adverse observations could raise concerns about regulatory compliance and future supply approvals. Investors should look for the detailed press release before drawing conclusions.